Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.

Literature DB >> 9652767

Elevated plasma levels of transforming growth factor (TGF)-beta1 and TGF-beta2 in patients with disseminated malignant melanoma.

K Krasagakis¹, D Thölke, B Farthmann, J Eberle, U Mansmann, C E Orfanos.

Abstract

Overexpression of transforming growth factor-beta isoforms (TGF-beta1, -beta2, -beta3) has been previously reported in human melanoma cell lines and tumours. The aim of the present study was to evaluate the plasma levels of TGF-beta isoforms in melanoma patients. Significantly elevated levels of TGF-beta1 (4.2 x the controls, P = 0.0094) and of TGF-beta2 (1.5 x the controls, P = 0.012) but not of TGF-beta3 were measured in patients with disseminated but not locoregional melanoma. These results indicate systemic circulation of potentially immunosuppressive peptides of the TGF-beta family in end-stage melanoma patients.

Entities: Disease Gene Species

Mesh：

Substances：

Year: 1998 PMID： 9652767 PMCID： PMC2150189 DOI： 10.1038/bjc.1998.245

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

13 in total

Review 1. The transforming growth factor-beta family.

Authors: J Massagué
Journal: Annu Rev Cell Biol Date: 1990

2. Inflammatory and immunomodulatory roles of TGF-beta.

Authors: S M Wahl; N McCartney-Francis; S E Mergenhagen
Journal: Immunol Today Date: 1989-08

3. Elevated plasma levels of TGF-beta 1 in patients with invasive prostate cancer.

Authors: V Ivanovic; A Melman; B Davis-Joseph; M Valcic; J Geliebter
Journal: Nat Med Date: 1995-04 Impact factor: 53.440

4. A highly immunogenic tumor transfected with a murine transforming growth factor type beta 1 cDNA escapes immune surveillance.

Authors: G Torre-Amione; R D Beauchamp; H Koeppen; B H Park; H Schreiber; H L Moses; D A Rowley
Journal: Proc Natl Acad Sci U S A Date: 1990-02 Impact factor: 11.205

5. Melanoma-associated expression of transforming growth factor-beta isoforms.

Authors: P Van Belle; U Rodeck; I Nuamah; A C Halpern; D E Elder
Journal: Am J Pathol Date: 1996-06 Impact factor: 4.307

6. Paracrine and autocrine regulation of human melanocyte and melanoma cell growth by transforming growth factor beta in vitro.

Authors: K Krasagakis; C Garbe; P I Schrier; C E Orfanos
Journal: Anticancer Res Date: 1994 Nov-Dec Impact factor: 2.480

7. Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors: J A Reed; N S McNutt; V G Prieto; A P Albino
Journal: Am J Pathol Date: 1994-07 Impact factor: 4.307

8. The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes.

Authors: U Lüscher; L Filgueira; A Juretic; M Zuber; N J Lüscher; M Heberer; G C Spagnoli
Journal: Int J Cancer Date: 1994-05-15 Impact factor: 7.396

9. Modulation of B16 melanoma growth and metastasis by anti-transforming growth factor beta antibody and interleukin-2.

Authors: S Wojtowicz-Praga; U N Verma; L Wakefield; J M Esteban; D Hartmann; A Mazumder; U M Verma
Journal: J Immunother Emphasis Tumor Immunol Date: 1996-05

10. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression.

Authors: H Tsushima; S Kawata; S Tamura; N Ito; Y Shirai; S Kiso; Y Imai; H Shimomukai; Y Nomura; Y Matsuda; Y Matsuzawa
Journal: Gastroenterology Date: 1996-02 Impact factor: 22.682

47 in total

1. IL-2-mediated augmentation of NK-cell activity and activation antigen expression on NK- and T-cell subsets in patients with metastatic melanoma treated with interferon-alpha and DTIC.

Authors: Gordana Konjević; Viktor Jović; Vladimir Jurisić; Sinisa Radulović; Svetislav Jelić; Ivan Spuzić
Journal: Clin Exp Metastasis Date: 2003 Impact factor: 5.150

2. Targeting miR-23a in CD8+ cytotoxic T lymphocytes prevents tumor-dependent immunosuppression.

Authors: Regina Lin; Ling Chen; Gang Chen; Chunyan Hu; Shan Jiang; Jose Sevilla; Ying Wan; John H Sampson; Bo Zhu; Qi-Jing Li
Journal: J Clin Invest Date: 2014-10-27 Impact factor: 14.808

3. TGF-β1-induced expression of Id-1 is associated with tumor progression in gastric cancer.

Authors: Huiying Ma; Ye Wei; Yongmei Leng; Shichao Li; Lingling Gao; Heng Hu; Long Chen; Fei Wang; Honglei Xiao; Chouwen Zhu; Chunmin Liang
Journal: Med Oncol Date: 2014-05-27 Impact factor: 3.064

Review 4. Targeting TGF-β Signaling for Therapeutic Gain.

Authors: Rosemary J Akhurst
Journal: Cold Spring Harb Perspect Biol Date: 2017-10-03 Impact factor: 10.005

Review 5. Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.

Authors: Kendra C Foley; Michael I Nishimura; Tamson V Moore
Journal: Melanoma Res Date: 2018-06 Impact factor: 3.599

6. Hemacytotoxicity and natural killer lytic index: New parameters to evaluate natural killer cell immunity for clinical use in cancer.

Authors: Hyung Gun Maeng; Su Jin Lee; Yun A Lee; Hye Jeong Lee; Young Joo Kim; Jong Kyun Lee; Jae Cheol Kim; Joungbum Choi
Journal: Oncol Lett Date: 2017-11-08 Impact factor: 2.967

7. Serum transforming growth factor-beta 1 (TGF-β1) levels have diagnostic, predictive, and possible prognostic roles in patients with melanoma.

Authors: Faruk Tas; Senem Karabulut; Ceren Tilgen Yasasever; Derya Duranyildiz
Journal: Tumour Biol Date: 2014-04-27